April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Safety, local tolerability and biodistribution of GS010 (AAV2/2-ND4), a gene therapy medicinal product in development for Leber Hereditary Optic Neuropathy (LHON)
Author Affiliations & Notes
  • Nitza Thomasson
    GenSight Biologics, Paris, France
  • Hélène Cwerman-Thibault
    Institut de la Vision, Paris, France
  • Sébastien Augustin
    Institut de la Vision, Paris, France
  • Manuel Simonuti
    Institut de la Vision, Paris, France
  • José-Alain Sahel
    Institut de la Vision, Paris, France
  • Didier Pruneau
    GenSight Biologics, Paris, France
  • Marie Montus
    Genethon, Evry, France
  • Anne Galy
    GenSight Biologics, Paris, France
  • Marisol Corral-Debrinski
    Institut de la Vision, Paris, France
  • Footnotes
    Commercial Relationships Nitza Thomasson, GenSight Biologics (E); Hélène Cwerman-Thibault, None; Sébastien Augustin, None; Manuel Simonuti, None; José-Alain Sahel, GenSight Biologics (C); Didier Pruneau, GenSight Biologics (E); Marie Montus, None; Anne Galy, GenSight Biologics (E); Marisol Corral-Debrinski, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3340. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nitza Thomasson, Hélène Cwerman-Thibault, Sébastien Augustin, Manuel Simonuti, José-Alain Sahel, Didier Pruneau, Marie Montus, Anne Galy, Marisol Corral-Debrinski; Safety, local tolerability and biodistribution of GS010 (AAV2/2-ND4), a gene therapy medicinal product in development for Leber Hereditary Optic Neuropathy (LHON). Invest. Ophthalmol. Vis. Sci. 2014;55(13):3340.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: LHON is a severe optic neuropathy leading to blindness and results, in most cases, from a point mutation in the mitochondrial NADH dehydrogenase subunit 4 gene (ND4). Corral-Debrinsky and Sahel’s team at Institut de la Vision in Paris demonstrated that optimized allotopic expression of GS010 rescued respiratory function of LHON fibroblasts in vitro, and restored vision in a rat model of LHON. In the present GLP study, we investigated the toxicity and biodistribution of intravitreally (IVT)-administered GS010 in non-human primates.

Methods: Cynomolgus monkeys (n=3/group/sex) received a single IVT injection of GS010 (low and high dose) or its vehicle and were sacrificed at 3 or 6 months after injection. In addition to regular systemic toxicity evaluation, local tolerability as well as local morphological and functional changes was carefully assessed using slit lamp and fundus photography, OCT-SLO imaging, IOP measurements and ocular histopathology. Persistence and shedding were evaluated in various organs and fluids.

Results: (1) GS010 did not cause toxicity in ocular tissues and was generally well tolerated though 8/18 case of low-grade anterior uveitis were observed at the high dose at 3 months; (2) Vector DNA was essentially found in the retina and anterior segment of the eye, and was not detected in brain, gonads, cerebellum, heart, prostate, kidney, lung, ovary, seminal vesicle, testis, skin, skeletal muscle, and visual cortex; (3) ND4 mRNA was detected in retinal ganglion cells 3 months after IVT injection

Conclusions: The GLP toxicity and biodistribution study in non-human primate allowed to determine a well-tolerated dose and further highlighted that ND4 mRNA is expressed in retinal ganglion cells. Based on these data and extensive pharmacological studies, we expect that GS010 represents a promising treatment of LHON. In this regard, a Phase I/II clinical trial is due to start Q1 2014.

Keywords: 538 gene transfer/gene therapy  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.